Leerink raised the firm’s price target on Insmed (INSM) to $115 from $100 and keeps an Outperform rating on the shares. The firm notes Insmed reported Phase 2b PAH data with TPIP that exceeded all expectations, with a statistically significant and clinically meaningful 6MWD benefit. Leerink remains positive on the stock ahead of the brensocatib launch later this summer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Morning Movers: Insmed jumps, United Therapeutics falls after TPIP study results
- Liquidia falls after Insmed’s TPIP meets endpoints in study
- United Therapeutics falls after Insmed’s TPIP meets endpoints in study
- Insmed Announces Positive Phase 2b Study Results
- Insmed’s Inhalation Powder meets endpoints in Phase 2b PAH trial